Heat-shock protein inhibitor could expand cisplatin's reach in cancer treatment

Researchers found that combining the drug onalespib with cisplatin—a standard chemotherapy—may overcome resistance that limits the older drug's effectiveness. The finding could extend cisplatin's clinical utility and potentially reduce costs, since the decades-old drug is far cheaper than newer alternatives.

Originaltitel: Correction: Overcoming limitations of cisplatin therapy by additional treatment with the HSP90 inhibitor onalespib